Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World

OBJECTIVE: To estimate the lifetime cost utility of two antiretroviral regimens (once-daily atazanavir plus ritonavir [ATV+r] versus twice-daily lopinavir/ritonavir [LPV/r]) in Italian human immunodeficiency virus (HIV)-infected patients naïve to treatment. DESIGN: With this observational retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Foglia, Emanuela, Bonfanti, Paolo, Rizzardini, Giuliano, Bonizzoni, Erminio, Restelli, Umberto, Ricci, Elena, Porazzi, Emanuele, Scolari, Francesca, Croce, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584032/
https://www.ncbi.nlm.nih.gov/pubmed/23460905
http://dx.doi.org/10.1371/journal.pone.0057777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584032/
https://www.ncbi.nlm.nih.gov/pubmed/23460905
http://dx.doi.org/10.1371/journal.pone.0057777

Ejemplares similares